Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO Paul Anderson talked with Proactive’s Tylah Tully about the company’s key achievements in 2024 and its ambitious plans for 2025. Anderson highlighted the success of Remplir, their innovative nerve repair product, which launched in Australia to strong distributor uptake and achieved reimbursement. This success drove record revenues for three consecutive quarters and bolstered Orthocell’s share price and market capitalisation. Anderson explained how Remplir revolutionises nerve repair by minimising sutures, reducing surgical damage, and improving patient recovery times. Orthocell is advancing global expansion plans, with regulatory submissions in the US, Canada, Thailand, Europe, and Brazil. “This product is addressing a strong unmet clinical need,” Anderson stated, emphasising the company’s goal of capturing a 20% share of the $3.2 billion global nerve repair market. In 2025, Orthocell aims to strengthen its US infrastructure, collaborate with leading surgeons, and scale Remplir’s commercialisation worldwide. #ProactiveInvestors #Orthocell #Remplir #NerveRepair #ASXOCC #HealthcareInnovation #MedicalDevices #FDAApproval #GlobalExpansion #ProactiveStudio #2025Growth